Wall Street Analyst Resumed Vaxart Inc. [VXRT]. What else is Wall St. saying

Vaxart Inc. [NASDAQ: VXRT] surged by $0.02 during the normal trading session on Monday and reaching a high of $1.07 during the day while it closed the day at $1.05. The company report on December 1, 2022 that Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants.

Vaxart Inc. stock has also loss -10.26% of its value over the past 7 days. However, VXRT stock has declined by -60.82% in the 3 months of the year. Over the past six months meanwhile, it has lost -62.90% and lost -83.25% year-on date.

The market cap for VXRT stock reached $152.50 million, with 131.25 million shares outstanding and 130.21 million shares in the current float. Compared to the average trading volume of 3.12M shares, VXRT reached a trading volume of 5596955 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Vaxart Inc. [VXRT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VXRT shares is $7.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VXRT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Vaxart Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 29, 2021. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on November 02, 2021, representing the official price target for Vaxart Inc. stock. Previously, the target price had yet another drop from $13 to $9, while B. Riley Securities kept a Neutral rating on VXRT stock.

The Average True Range (ATR) for Vaxart Inc. is set at 0.12, with the Price to Sales ratio for VXRT stock in the period of the last 12 months amounting to 762.51. The Price to Book ratio for the last quarter was 1.09, with the Price to Cash per share for the same quarter was set at 0.79.

VXRT stock trade performance evaluation

Vaxart Inc. [VXRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.26. With this latest performance, VXRT shares dropped by -32.26% in over the last four-week period, additionally sinking by -62.90% over the last 6 months – not to mention a drop of -83.12% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VXRT stock in for the last two-week period is set at 33.30, with the RSI for the last a single of trading hit 32.74, and the three-weeks RSI is set at 33.75 for Vaxart Inc. [VXRT]. The present Moving Average for the last 50 days of trading for this stock 1.5318, while it was recorded at 1.0780 for the last single week of trading, and 3.2262 for the last 200 days.

Vaxart Inc. [VXRT]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Vaxart Inc. [VXRT] shares currently have an operating margin of -7819.17. Vaxart Inc.’s Net Margin is presently recorded at -7900.22.

Return on Equity for this stock declined to -45.33, with Return on Assets sitting at -37.71.

Vaxart Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.50 and a Current Ratio set at 5.50.

Vaxart Inc. [VXRT]: Insider Ownership positions

There are presently around $53 million, or 39.50% of VXRT stock, in the hands of institutional investors. The top three institutional holders of VXRT stocks are: STATE STREET CORP with ownership of 14,070,207, which is approximately 11.034% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 9,113,005 shares of the stock with an approximate value of $9.57 million in VXRT stocks shares; and VANGUARD GROUP INC, currently with $7.34 million in VXRT stock with ownership of nearly 5.153% of the company’s market capitalization.

Positions in Vaxart Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 73 institutional holders increased their position in Vaxart Inc. [NASDAQ:VXRT] by around 8,331,443 shares. Additionally, 53 investors decreased positions by around 2,119,563 shares, while 32 investors held positions by with 40,333,826 shares. The mentioned changes placed institutional holdings at 50,784,832 shares, according to the latest SEC report filing. VXRT stock had 18 new institutional investments in for a total of 325,834 shares, while 16 institutional investors sold positions of 246,442 shares during the same period.


Please enter your comment!
Please enter your name here